MedTrace Logo

Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor

NCT02983786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2022-09-02

No results posted yet for this study

Summary

The goals of the project are to evaluate a noninvasive monitor of brain metabolism and blood flow in critically ill humans. If validated, such a reliable noninvasive brain blood flow and metabolism monitor, by allowing physiologic and pharmacologic decisions based on real-time brain physiology, potentially will become an important tool for clinicians in their efforts to prevent additional brain tissue death in patients admitted with stroke, brain hemorrhage and traumatic brain injury.

Conditions

Interventions

DRUG

Indocyanine Green

ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).

Sponsors & Collaborators

Principal Investigators

  • W. Andrew Kofke, MD · University of Pennsylvania Health System

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-10-31
Completion
2022-05-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02983786 on ClinicalTrials.gov